US EditionVenus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
- Venus Medtech announced its financial results for the year ending December 31, 2024, in Hong Kong.
- Venus Medtech's "Profitability-First" strategy drove increases in commercial profit and reduced EBITDA losses.
- Commercial profit increased 112.60% to RMB97.7 million, and products reached over 650 hospitals nationwide.
- CEO Lim Hou-Sen stated, "2024 was a transformative year," prioritizing profitability and global expansion.
- Venus Medtech expanded globally with VenusP-Valve entering 63 markets and a total footprint of nearly 70 markets.
34 Articles
34 Articles
The Daily Advance
Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
HONG KONG, April 21, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31,…
Venus Medtech Reports 2024 Profit Surge on Innovation and Global Expansion
HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges. Key Financial Highlights Revenue: RMB471 million, w…
Coverage Details
Bias Distribution
- 69% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
